KRAS and cancer: It was also reported that cancer cells with KRAS mutations could recruit myeloid-derived suppressor cells to secrete granulocyte–macrophage colony-stimulating factor, effectively limiting the infiltration level and decreasing the antitumor activities of CD8+ cytotoxic T-cells [35].